On Tuesday, April 25th, after the market closes, USANA Health Sciences (NYSE: USNA) will report its highly anticipated earnings. Analysts predict quarterly earnings of $0.77 per share. This vital data will likely affect USANA’s stock performance, therefore investors and market observers eagerly await it.
In a February 13th research report, DA Davidson raised their price objective from $49.00 to $52.50 and gave the stock a “neutral” rating. On March 10, StockNews.com raised USANA Health Sciences from “buy” to “strong buy.”
At $61.01, Joshua Foukas sold 3,771 shares.
While investor sentiment is split about USANA’s earnings forecast, some insiders have sold shares recently. Brent Neidig sold 1,872 shares at $61.89 in February, while Joshua Foukas sold 3,771 shares at $61.01.
Corporate insiders sold 24,632 shares worth over $1.4 million in the last three months. Interestingly, insiders still own 0.33% of the stock, reflecting optimism about USANA’s long-term potential.
The sales might be perceived as a lack of faith from insiders or as taking advantage of high stock prices, making many investors apprehensive before forming firm conclusions, especially with news cycles becoming more unpredictable than ever.
We expect shareholders and financial analysts to learn a lot from this week’s earnings call about the revolutionary health science company’s Q2 and beyond plans.
Network Hype Team